Tianjin, China

Lulu Lv

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 8.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Inventor Lulu Lv

Introduction

Lulu Lv is a prominent inventor based in Tianjin, China. She has made significant contributions to the field of cell therapy, particularly in the development of modified immune cells. With a total of 3 patents to her name, her work is paving the way for advancements in medical treatments.

Latest Patents

Lulu Lv's latest patents include innovative methods for preparing modified immune effector cells. One of her notable patents is titled "Plasmid combination and application thereof in preparing modified immune cells." This patent describes a method that utilizes a four-plasmid system to create modified immune effector cells. The process involves forming a lentivirus using four plasmids within 293T cells, extracting the lentivirus, and transfecting immune effector cells to express a chimeric antigen receptor. Another significant patent is "CD19-targeted chimeric antigen receptor and use thereof." This patent details a chimeric antigen receptor comprising a specific amino acid sequence, along with methods for preparing immune effector cells and their applications.

Career Highlights

Lulu Lv is currently employed at Juventas Cell Therapy Ltd., where she continues to innovate in the field of cell therapy. Her work focuses on enhancing the efficacy of immune cells for therapeutic purposes.

Collaborations

Lulu collaborates with talented individuals such as Lin Shi and Rui Wang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Lulu Lv's contributions to the field of cell therapy through her patents and work at Juventas Cell Therapy Ltd. highlight her role as a leading inventor in the industry. Her innovative approaches are set to make a lasting impact on medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…